FIBRX Derm is committed to the development of decorin, an anti-scarring therapy, for Dystrophic Epidermolysis Bullosa, a devastating, genetic, skin blistering disease. Decorin, a naturally occurring protein, binds collagen and facilitates the proper development, maintenance, and repair of structural components of the extracellular matrix. We are developing a gel formulation of human recombinant Decorin, an engineered form of the natural anti-scarring protein, to promote healthy tissue regeneration and reduce excessive scarring.
FIBRX Derm has obtained venture philanthropy funding from the EB Research Partnership and the EB Medical Research Foundation.
